Introduction
============

Lung cancer and chronic obstructive pulmonary disease (COPD) are both common diseases worldwide. Lung cancer is the leading cause of cancer related deaths with a 5-year survival rate of about 16%.[@b1-copd-11-043] Meanwhile, COPD is the fourth leading cause of death globally, which is expected to become the third by 2020.[@b2-copd-11-043] Epidemiological survey discovers that the presence of COPD increases the risk of lung cancer by 4.5-fold.[@b3-copd-11-043],[@b4-copd-11-043] Moreover, ∼40%--70% of lung cancer patients complicate with COPD.[@b5-copd-11-043] Patients undergoing pulmonary resection for lung cancer with COPD are thought to be at increased risk of short-term complications and surgery-related death. Furthermore, Zhai et al[@b6-copd-11-043] found that patients with COPD had increased risk of worse overall survival and progression-free survival. For patients with stage I non-small-cell lung cancer (NSCLC), the decline in overall survival after lobectomy was associated with lower pulmonary function.[@b7-copd-11-043] However, whether the severity of COPD affects recurrence-free survival (RFS) after complete resection for NSCLC remains unclear. The purpose of this study was to investigate the impact of COPD on postoperative recurrence in patients with resectable NSCLC.

Material and methods
====================

Patients
--------

We performed a retrospective review of consecutive patients with NSCLC who underwent lobectomies with systematic mediastinal lymph node dissection at our hospital from January 2008 to June 2011. This study was approved by the Institutional Review Board of the China--Japan Friendship Hospital in accordance with the Declaration of Helsinki. All patients signed written informed consent prior to surgery. Histological type and pathological stage for each patient were determined according to 2004 World Health Organization (WHO) Classification of Lung Tumors and the 7th edition of TNM classification for lung cancer proposed by the International Association for the Study of Lung Cancer (IASLC).[@b8-copd-11-043] The inclusion criteria were: 1) primary NSCLC confirmed pathologically; 2) underwent standard pulmonary function test a week prior to surgery; 3) lobectomy and systematic lymph node dissection were performed without either microscopic or macroscopic residual tumor. The exclusion criteria were: 1) presented with simultaneous or sequential second primary cancers; 2) had neoadjuvant therapy (chemotherapy and/or radiation therapy); 3) the presence of pneumonia, atelectasis, pulmonary interstitial fibrosis, and other diseases that might affect pulmonary function before surgery; 4) incomplete resection with macroscopic or microscopic residual disease; 5) died of complications within 1 month after surgery.

Evaluation of pulmonary function
--------------------------------

Pulmonary function was measured by a computerized spirometer (Master Screen Body, Jaeger, Würzburg, Germany) according to the standardization criteria of the American Thoracic Society.[@b9-copd-11-043] Measurements included forced vital capacity (FVC), percentage of FVC (FVC%), forced expiratory volume in 1 second (FEV~1~), percentage of FEV~1~ (FEV~1~%), and FEV~1~/FVC ratio.

The diagnosis and severity was determined by spirometric criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).[@b10-copd-11-043] FEV~1~/FVC\<70% was diagnosed as COPD. The severity of COPD was graded by the degree of decrease in FEV~1~: 1) FEV~1~≥80% predicted, mild (GOLD-1); 2) 50%≤FEV~1~\<80% predicted, moderate (GOLD-2); 30%≤FEV~1~\<50% predicted, severe (GOLD-3); and FEV~1~\<30% predicted, extremely severe (GOLD-4).

Follow-up
---------

Patients were initially followed up at 1 month after resection by the thoracic surgeon, then at 3-month intervals for the first 2 years, and thereafter every 6--12 months. The postoperative evaluations included clinical assessments, tumor marker measurement, chest computed tomography (CT), abdominal CT or ultrasonography, CT or magnetic resonance imaging (MRI) of the brain and bone scintigraphy. All of the patients were followed. The median follow-up period was 50 months (range: 10--83 months). Recurrences were diagnosed by physical examination and diagnostic imaging. Second primary lung cancer was differentiated from recurrence according to the criteria proposed previously.[@b11-copd-11-043] Pathological confirmation of recurrence was made when clinically feasible. RFS was defined as the duration from the date of surgery to the most recent follow-up contact or to the date of recurrence or death.

Statistical analysis
--------------------

Categorical variables were expressed as counts and percentages, and continuous variables were expressed as mean ± standard deviation. One-way analysis of variance was performed to compare continuous variables; the *χ*^2^ (chi-square) test or Fisher's exact test as appropriate was applied to compare categorical variables among groups. Correlations between variables were determined using the Spearman's rank test. Survival curves were generated by Kaplan--Meier method and the statistical significance of differences between groups were assessed by log-rank test. Multivariate analyses were performed by means of a Cox proportional hazards model. The software package SPSS version 20.0 (IBM Corp., Armonk, NY, USA) was used for all statistical analyses. Statistical significance was considered at *P*\<0.05.

Results
=======

The clinicopathological features of the patients are listed in [Table 1](#t1-copd-11-043){ref-type="table"}. A total of 421 consecutive cases were included in this study, including 260 males and 161 females. The median age was 67 years (range: 32--84 years). Of these patients, 273 had smoking history. Pathological TNM stages were stage I in 356 patients, stage II in 36 patients, and stage IIIA in 29 patients. During the follow-up period, recurrence was observed in 83 patients, 32 cases had local-regional recurrences, distant metastases were identified in 22 cases, both local-regional recurrence and distant metastases occurred in nine cases. The most common site of local-regional recurrence was the lung in 24 cases, followed by mediastinal lymph node in 16 cases, pleura in eight cases, and bronchial stump in four cases. The brain was the most common site of distant metastases (ten cases), followed by the bone (eight cases), the liver (two cases), and the adrenals (one case). A total of 172 patients were diagnosed with COPD, including 124 mild cases (GOLD-1), 46 moderate cases (GOLD-2), and two severe cases (GOLD-3). The whole study population was stratified into non-COPD, mild COPD, and moderate/severe COPD groups. The elevated severity of COPD categories tended to include male, older individuals with a history of smoking, advanced pathological stage and non-adenocarcinoma histology. The postoperative recurrent rate was higher as the severity of COPD increased. The three groups were similar in terms of tumor size, bearing lobe, and adjuvant therapy. Preoperative pulmonary function of patients is summarized in [Table 2](#t2-copd-11-043){ref-type="table"}. As the severity of COPD increased, FVC, FVC%, FEV~1~, FEV~1~%, and FEV~1~/FVC% all decreased significantly (*P*\<0.05, [Table 2](#t2-copd-11-043){ref-type="table"}).

The 1-, 3-, and 5-year RFS was 96.7%, 85.2%, and 72.7%, respectively ([Figure 1](#f1-copd-11-043){ref-type="fig"}). The 5-year RFS in NSCLC patients with COPD was 64.0%, significantly lower than that of non-COPD patients (78.1%) (*P*=0.002). The Kaplan--Meier survival curves indicated that COPD was associated with decreased RFS in either all patients or pathological stage I patients (*P*=0.002 and *P*=0.003, respectively) ([Figure 2](#f2-copd-11-043){ref-type="fig"}). Subgroup analysis indicated that the 5-year RFS was 70.4% for mild COPD group, which was comparable with that of non-COPD group (*P*=0.115). However, the 5-year RFS of moderate/severe COPD group was 46.4%, significantly lower than that of non-COPD group (*P*\<0.001) and mild COPD group (*P*=0.001) ([Figure 3A](#f3-copd-11-043){ref-type="fig"}). In pathological stage I patients, the 5-year RFS was 83.1% for non-COPD group, 76.8% for mild COPD group (*P*=0.100). However, the 5-year RFS of moderate/severe COPD group was 54.1%, significantly lower than that of non-COPD group (*P*\<0.001) and mild COPD group (*P*=0.003) ([Figure 3B](#f3-copd-11-043){ref-type="fig"}). Univariate analysis revealed that the age, sex, smoking history, tumor size, histological type, and pathological staging were all significant predictors of RFS ([Table 3](#t3-copd-11-043){ref-type="table"}). These variables identified by univariate analysis were included in Cox proportional hazards model to verify independent prognostic factors. Multivariate analysis demonstrated that moderate/severe COPD was an independent prognostic factor for RFS (hazard ratio (HR) =1.718, 95% confidence interval (CI): 1.086--2.919), along with the age, sex, and pathological stage ([Table 4](#t4-copd-11-043){ref-type="table"}).

Discussion
==========

The aim of this study was to examine the correlation between COPD and postoperative recurrence in patients with resected NSCLC. In the present study, we found that coexisting COPD was associated with worse RFS. Furthermore, our results indicate that moderate/severe COPD is an independent risk factor for recurrence, while mild COPD does not carry a similar risk.

Both COPD and lung cancer are common fatal diseases. They share some risk factors in common, including smoking, environmental exposure, and genetic predisposition. COPD also plays an important role in the pathogenesis and progression of lung cancer.[@b12-copd-11-043] Thus, there is a close relationship between them and the coexistence is frequent.[@b13-copd-11-043],[@b14-copd-11-043] The risk of lung cancer in patients with COPD is fivefold greater compared with smokers without COPD.[@b4-copd-11-043] In COPD cohort studies, the incidence of lung cancer was 16.7 cases per 1,000 person-years, and ∼20%--30% of COPD patients died of lung cancer.[@b4-copd-11-043],[@b5-copd-11-043] Moreover, the risk of lung cancer increased in proportion to the severity of COPD.[@b15-copd-11-043],[@b16-copd-11-043] On the other hand, the prevalence of COPD diagnosed by spirometry in newly diagnosed lung cancer patients was found to be 40%--70%.[@b5-copd-11-043],[@b17-copd-11-043] In our study, 40.8% of patients with NSCLC had coexisting COPD, consistent with previous reports. As adequate pulmonary reserve was necessary for lobectomy, the majority of COPD patients in our cohort were mild to moderate; only two patients were severe. Our results confirmed that FEV~1~% was positively correlated with other pulmonary function indicators, including FVC, FVC%, FEV~1~, and FEV~1~/FVC levels. The stratification system based on FEV~1~% provides an accurate assessment of pulmonary function status for COPD patients. We found that increased severity of COPD was more frequent in males, elders, smokers, and non-adenocarcinoma patients. This might be explained by the following: cigarette exposure-induced inflammatory response contributes to the development of COPD and squamous cell lung carcinoma, the prevalence of smokers is more frequent in the male population as well as non-adenocarcinoma patients, and the age reflects the sum of cumulative exposures throughout life.

The correlation of COPD severity with the incidence of cardiopulmonary complications after surgery has been well established in previous studies. However, the effect of COPD on the survival after resection of lung cancer is still uncertain. Several studies reported that NSCLC with COPD has a poor prognosis. Gullon et al[@b18-copd-11-043] found that pulmonary emphysema was an adverse prognostic factor in NSCLC. Kiri et al[@b19-copd-11-043] reported that the 3-year survival of lung cancer patients with COPD was almost half that of patients without COPD. Sekine et al[@b20-copd-11-043] showed that COPD was a risk factor for predicting survival after surgical resection for stage IA lung cancer. However, Arca et al[@b21-copd-11-043] reported that the survival of lung cancer patients with COPD was longer. Another two studies did not find any significant correlation between COPD and prognosis in patients with NSCLC.[@b22-copd-11-043],[@b23-copd-11-043] The discrepant findings may be due to the differences in ethnicity, inclusion criteria, sample size, and treatment method. To minimize the effect of confounders, we only included complete lobar resection other than sublobar resection, pneumonectomy or incomplete resection. Our findings indicate that poor oncologic outcome in patients with COPD is due to a higher risk of tumor recurrence. The RFS of NSCLC with COPD was significantly worse than that without COPD. Subgroup analysis revealed that moderate/severe COPD was the main cause while mild COPD did not have a significant impact on RFS.

Several possible mechanisms may explain this association. The tumor cells originating from the lung parenchyma with excessive inflammatory responses tend to be more aggressive.[@b3-copd-11-043] Chronic inflammation promotes tumor proliferation, angiogenesis, and metastasis through the production of inflammatory mediators, including chemokines, cytokines, and secretion of C-reactive protein (CRP).[@b24-copd-11-043] It has been reported that a variety of inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and IL-6, promote the survival of circulating tumor cells and epithelial-mesenchymal transition, which is important for the invasion and metastasis of NSCLC.[@b25-copd-11-043],[@b26-copd-11-043] Genetic mutation and abnormal gene expression may also accelerate cancer recurrence and metastasis in patients with COPD.[@b14-copd-11-043] The activation of signal transduction pathways including nuclear-factor kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3) enhance invasion and metastasis of tumor cells. There is some potential overlap in regions linked to COPD and lung cancer on chromosomes 6q and 12p.[@b27-copd-11-043] Therefore, further studies are needed to elucidate the potential underlying mechanisms.

Conclusion
==========

We found that moderate/severe COPD was an independent unfavorable prognostic factor after complete resection for NSCLC. The severity of COPD based on FEV~1~ can be a useful tool to identify patients at high risk for recurrence. Our results suggest that comprehensive therapeutic strategies are required to improve RFS of resectable lung cancer with moderate to severe COPD.
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![Kaplan--Meier survival curves of recurrence-free survival for the whole study population.](copd-11-043Fig1){#f1-copd-11-043}

![Kaplan-Meier curves for recurrence-free survival stratified by COPD.\
**Notes:** (**A**) Kaplan--Meier survival curves for patients with NSCLC according to the presence of COPD (*P*=0.002). (**B**) Kaplan--Meier survival curves for patients with pathological stage I NSCLC according to the presence of COPD (*P*=0.003).\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; NSCLC, non-small-cell lung cancer.](copd-11-043Fig2){#f2-copd-11-043}

![Kaplan-Meier curves for recurrence-free survival stratified by COPD severity.\
**Notes:** (**A**) Kaplan--Meier survival curves for patients with NSCLC according to COPD severity (*P*\<0.001). (**B**) Kaplan--Meier survival curves for patients with pathological stage I NSCLC according to COPD severity (*P*\<0.001).\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; NSCLC, non-small-cell lung cancer.](copd-11-043Fig3){#f3-copd-11-043}

###### 

Patient characteristics and the severity of COPD

  Characteristics         Non-COPD, n=249 (%)   Mild COPD, n=124 (%)   Moderate/severe COPD, n=48 (%)   *P*-value
  ----------------------- --------------------- ---------------------- -------------------------------- -----------
  Age (years)                                                                                           \<0.001
   \<65                   118 (47.4)            24 (19.4)              13 (27.1)                        
   ≥65                    131 (52.6)            100 (80.6)             35 (72.9)                        
  Sex                                                                                                   \<0.001
   Female                 117 (47.0)            35 (28.2)              9 (18.8)                         
   Male                   132 (53.0)            89 (71.8)              39 (81.3)                        
  Smoking history                                                                                       \<0.001
   No                     111 (44.6)            33 (26.6)              4 (8.3)                          
   Yes                    138 (55.4)            91 (73.4)              44 (91.7)                        
  Tumor size (cm)                                                                                       0.405
   ≤3                     214 (85.9)            100 (80.6)             41 (85.4)                        
   \>3                    35 (14.1)             24 (19.4)              7 (14.6)                         
  Tumor location                                                                                        0.289
   Left upper lobe        65 (26.1)             41 (33.1)              8 (16.7)                         
   Left lower lobe        37 (14.9)             16 (12.9)              8 (16.7)                         
   Right upper lobe       83 (33.3)             35 (28.2)              14 (29.2)                        
   Right middle lobe      18 (7.2)              9 (7.3)                2 (4.2)                          
   Right lower lobe       46 (18.5)             23 (18.5)              16 (33.3)                        
  Procedure                                                                                             0.385
   VATS                   133 (53.4)            73 (58.9)              23 (47.9)                        
   Open                   116 (46.6)            51 (41.1)              25 (52.1)                        
  Histology                                                                                             \<0.001
   Ad                     213 (85.5)            78 (62.9)              27 (56.3)                        
   Non-Ad                 36 (14.5)             46 (37.1)              21 (43.7)                        
  Pathological stage                                                                                    0.002
   I                      220 (88.4)            103 (83.1)             33 (68.8)                        
   II                     14 (5.6)              16 (12.9)              6 (12.5)                         
   III                    15 (6.0)              5 (4.0)                9 (18.8)                         
  Adjuvant chemotherapy                                                                                 0.773
   No                     220 (88.4)            107 (86.3)             41 (85.4)                        
   Yes                    29 (11.6)             17 (13.7)              7 (14.6)                         
  Recurrence                                                                                            \<0.001
   No                     211 (84.7)            98 (79.0)              29 (60.4)                        
   Yes                    38 (15.3)             26 (21.0)              19 (39.6)                        
  Recurrence style                                                                                      0.648
   Local-regional         21 (55.3)             17 (65.4)              14 (73.7)                        
   Distant                12 (31.6)             7 (26.9)               3 (15.8)                         
   Both                   5 (13.2)              2 (7.7)                2 (10.5)                         

**Abbreviations:** Ad, adenocarcinoma; COPD, chronic obstructive pulmonary disease; VATS, video-assisted thoracoscopic surgery.

###### 

Comparison of pulmonary function among groups with different severity of COPD

  Pulmonary function tests   Non-COPD (n=249)   Mild COPD (n=124)   Moderate/severe COPD (n=48)   *P*-value
  -------------------------- ------------------ ------------------- ----------------------------- -----------
  FVC (L)                    3.30±0.84          3.08±0.74           3.02±0.81                     0.022
  %FVC (%)                   113.35±15.97       107.19±17.38        97.14±17.46                   \<0.001
  FEV~1~ (L)                 2.21±0.77          1.90±0.72           1.58±0.53                     \<0.001
  %FEV~1~ (%)                109.61±16.68       82.93±18.50         69.93±9.44                    0.045
  FEV~1~/FVC (%)             78.04±6.32         63.39±5.43          54.41±9.20                    \<0.001

**Note:** The continuous variables are presented as mean ± SD.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in I second; FVC, forced vital capacity.

###### 

Univariate analysis of risk factors associated with recurrence-free survival

  Characteristics         Cases (n=421)   5-year RFS rate (%)   *P*-value
  ----------------------- --------------- --------------------- -----------
  Age (years)                                                   0.001
   \<65                   155             82.7                  
   ≥65                    266             65.4                  
  Sex                                                           \<0.001
   Female                 161             85.9                  
   Male                   260             63.8                  
  Smoking history                                               \<0.001
   No                     148             82.8                  
   Yes                    273             66.7                  
  COPD                                                          \<0.001
   Non                    249             78.1                  
   Mild                   124             70.4                  
   Moderate/severe        48              46.4                  
  Tumor size (cm)                                               0.002
   ≤3                     355             74.8                  
   \>3                    66              58.5                  
  Tumor location                                                0.372
   Left upper lobe        114             69.6                  
   Left lower lobe        61              68.5                  
   Right upper lobe       132             78.4                  
   Right middle lobe      29              79.2                  
   Right lower lobe       85              68.2                  
  Procedure                                                     0.145
   VATS                   229             75.2                  
   Open                   192             67.3                  
  Histology                                                     \<0.001
   Ad                     318             77.3                  
   Non-Ad                 103             56.9                  
  Pathological stage                                            \<0.001
   I                      356             78.4                  
   II                     36              54.3                  
   III                    29              43.2                  
  Adjuvant chemotherapy                                         0.351
   No                     368             74.4                  
   Yes                    53              68.3                  

**Abbreviations:** Ad, adenocarcinoma; COPD, chronic obstructive pulmonary disease; RFS, recurrence-free survival; VATS, video-assisted thoracoscopic surgery.

###### 

Multivariate analysis of risk factors for recurrence-free survival with proportional hazard model

  Variables                          *χ*^2^   Hazard ratio   95% CI         *P*-value
  ---------------------------------- -------- -------------- -------------- -----------
  Age (≥65 vs \<65)                  8.496    1.878          1.229--2.868   0.004
  Sex (male vs female)               6.394    2.055          1.176--3.593   0.011
  Smoking history (yes vs no)        0.799    1.296          0.734--2.290   0.371
  Moderate/severe COPD (yes vs no)   5.234    1.718          1.086--2.919   0.022
  Tumor size (\>3 cm vs ≤3 cm)       1.333    1.357          0.808--2.277   0.248
  Histology (non-Ad vs Ad)           1.334    1.290          0.837--1.987   0.248
  Pathological stage (II/III vs I)   29.509   3.363          2.171--5.210   \<0.001

**Abbreviations:** Ad, adenocarcinoma; CI, confidence interval; COPD, chronic ob structive pulmonary disease.
